First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).
1 finding from 1 review
Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to lower total failure: day 28 (unadjusted) compared with artemether‐lumefantrine (AL) (low certainty).
2 findings from 1 review
Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal ALT increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal AST increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal bilirubin increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement of clinical status: all initial symptoms resolved (asymptomatic) at day 14 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in improvement of clinical status: all initial symptoms resolved… (low certainty).
1 finding from 1 review
Intervention not reported
QoL (physical component) at up to 28 days, measured on the PROMIS Global‐10 scale and normalized to values from 16.2, low QoL, to 67.2, maximum QoL · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in qoL (physical component) at up to 28 days, measured on the PROMIS… (high certainty).
1 finding from 1 review
Intervention not reported
QoL (mental component) at up to 28 days, measured on the PROMIS Global‐10 scale and normalized to values from 21.2, low QoL, to 67.6, maximum QoL · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in qoL (mental component) at up to 28 days, measured on the PROMIS… (high certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at day 7 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in viral clearance at day 7 (low certainty).
1 finding from 1 review
Intervention not reported
Worsening of clinical status: participants with new need for invasive mechanical ventilation or death at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes worsening of clinical status: participants with new need for… (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement of clinical status: participants discharged alive at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in improvement of clinical status: participants discharged alive at day… (low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at day 7 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in viral clearance at day 7 (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in all‐cause mortality at day 28 (moderate certainty).
1 finding from 1 review
Intervention not reported
Worsening of clinical status: admission to hospital or death within 28 days · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in worsening of clinical status: admission to hospital or death within… (low certainty).
1 finding from 1 review
Total failure: day 28 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
Total failure day 28 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure [day 42 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
1 finding from 1 review
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
1 finding from 1 review